S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

BACKGROUND: Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC). We carried out a randomized, open-label, phase III trial to determine whether S-1 and irinotecan plus bevacizumab is noninferior to m...

詳細記述

保存先:
書誌詳細
出版年:Ann Oncol
主要な著者: Yamada, Y, Denda, T, Gamoh, M, Iwanaga, I, Yuki, S, Shimodaira, H, Nakamura, M, Yamaguchi, T, Ohori, H, Kobayashi, K, Tsuda, M, Kobayashi, Y, Miyamoto, Y, Kotake, M, Shimada, K, Sato, A, Morita, S, Takahashi, S, Komatsu, Y, Ishioka, C
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889030/
https://ncbi.nlm.nih.gov/pubmed/29293874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx816
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料